Can-Fite BioPharma Ltd. CANF
1.55 USD -0.11 (-6.63%)
At closeNov 11, 2026, 7:53 PM EST
1.55 0.00 0.00%
After hours · Nov 11, 7:53 PM ET
1.55 Day range 1.63
1.50 52-week range 12.40
- YTD
- -61.25%
- 1 year
- -80.63%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…
benzinga.com Can-Fite Announces 10-Yr Cancer-Free Survival In Advanced Liver Cancer Patient Treated With Namodenoson Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestoneRamat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma…
globenewswire.com Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study Patient from the Company's completed Phase II study remains cancer-free and in good health at the ten-year survival milestone Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma…
benzinga.com Can-Fite Biopharma To Pursue Global Licensing And Strategic Partnerships Using Its Phase IIa Pancreatic Cancer Results Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its…
globenewswire.com Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones Company to leverage positive Phase IIa pancreatic cancer results presented at ESMO 2026, two pivotal Phase III programs, and expanding patent protection to advance global partnering opportunities
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com Can-Fite BioPharma Says EAPO Issues Notification Of Readiness To Grant Patent Covering Use Of Piclidenoson For Treatment Of Diseases Associated With OCRL Deficiency Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione TelethonRamat…
globenewswire.com Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat…
benzinga.com Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months…
globenewswire.com Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39…
globenewswire.com Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel,…
benzinga.com Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of…
globenewswire.com Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
benzinga.com Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
benzinga.com Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
benzinga.com Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological…
globenewswire.com Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
- benzinga.com Can-Fite Says Blinded Overall Survival Observed Across Entire Patient Population In Ongoing Pivotal Phase III Study Of Namodenoson In Advanced HCC Appears Longer Than Originally Anticipated Based On Assumptions Underlying Study Design Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases,…
globenewswire.com Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
benzinga.com Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.…
globenewswire.com Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE…
globenewswire.com Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) --…- benzinga.com Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive resultsRamat Gan, Israel, Aug. 03, 2026 (GLOBE…
globenewswire.com Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE…- benzinga.com Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases,…
globenewswire.com Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
globenewswire.com Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small…- benzinga.com Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis Interim analysis to be conducted under an FDA- and EMA-agreed protocolRamat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage…
globenewswire.com Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a…- benzinga.com 11 Health Care Stocks Moving In Thursday's Intraday Session Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
benzinga.com HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8 HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ:RGC) stock moved…
benzinga.com Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, with updated follow-up data…
benzinga.com Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.
globenewswire.com Wall Street is Watching These Biotechs Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International…
benzinga.com Market-Moving News for July 1st NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom Energy shares are trading higher after the company announced it expanded its AI infrastructure…
globenewswire.com Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
benzinga.com Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic disease opportunity.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-market session. The company's market cap stands at $33.0 million. INVO Fertility (NASDAQ:IVF) shares…
- benzinga.com Market-Moving News for June 26th ON: -14% | ON stock has given up its prior gain. ON Semiconductor shares were trading higher after the company announced it will acquire Synaptics. IVF: 84% | INVO Fertility Acquires HRCFG For…
- benzinga.com Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseasesRamat Gan, Israel, June…
globenewswire.com Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June…- benzinga.com Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article Showing Broad Therapeutic Potential Of Lead Drug Candidates, Piclidenoson And Namodenoson, Across Multiple Major Diseases Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced…
- benzinga.com Can-Fite Highlights Pancreatic Cancer Drug Progress Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory…
benzinga.com Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article On Findings From Study Evaluating Piclidenoson For Treatment Of Canine Osteoarthritis Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced…- benzinga.com D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.